Business Wire

NTHU and DAICEL of Japan to Jointly Develop Revolutionary Desktop Chemical Plant

28.10.2021 12:00:00 EEST | Business Wire | Press release

Share

National Tsing Hua University (NTHU) and the well-known Japanese chemical company DAICEL announce a five-year joint project to integrate an innovative microfluidic system developed by scholar Kitamori Takehiko into the chemical manufacturing industry today. Total investment in the project is 450 million Japanese yen (approximately NT$110 million), and its potential to reduce energy consumption while lowering the production of carbon and waste is expected to set a new standard for sustainability in the chemical industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005388/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Prof. Kitamori Takehiko has developed an innovative microfluidic system which allows the mixing and extracting operations conventionally carried out with large-scale equipment to be performed using a glass chip the size of a business card. (Photo: National Tsing Hua University)

Prof. Kitamori, a world-renowned pioneer in microfluidic and nanofluidic technology and the former vice president of the University of Tokyo, has been serving as the Yushan Honorary Chair Professor of the Institute of Nanoengineering and Microsystems, Department of Power Mechanical Engineering at NTHU since 2020. Building on his previous research conducted at the University of Tokyo, he has developed an innovative microfluidic system which allows the mixing and extracting operations conventionally carried out with large-scale equipment to be performed using a glass chip the size of a business card and capable of combining thousands of microfluidic chips simultaneously, making it possible to create a “desktop chemical plant.”

Kitamori explained that it can be quite difficult to instantaneously mix several large barrels of chemicals with different temperatures and reaction speeds, and there may even be an explosion if the materials are not handled carefully. Thus the preferred way of blending chemicals is by passing it through a microchannel, which makes it possible to precisely control the amount of raw materials used, as well as the mixing sequence and conditions, thereby optimizing the quality of the final product.

Kitamori said that the aim of the project is to reduce the size of chemical production equipment, so that what is currently produced by a factory measuring 20 x 20 meters can be miniaturized into a system only two square meters in size. What’s more, such a system would use less energy and materials, making it less expensive, and would also produce less carbon.

Years ago, when DAICEL president Ogawa Yoshimi heard about the microfluidic technology developed by Kitamori, he was deeply impressed, and is now highly pleased that DAICEL is going to integrate this innovative technology into its operations. He is also looking forward to cooperating with NTHU in introducing this epoch-making manufacturing process to the world, which he also sees as a way of promoting sustainability and the circular economy.

Dr. Fan-gang Tseng, Vice President and Director of Research and Development, NTHU, said that he is very optimistic about the future development of the microfluidic chemical plant. He pointed out that the adoption of this microfluidic process by DAICEL—one of the largest chemical companies in Japan—and by Taiwan’s many small and medium-sized chemical factories would constitute a revolutionary leap forward, and could lead to similar processes being applied by the semiconductor and biomedical industry.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release

Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto

ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo

NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots

Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est

Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release

Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye